Variety of eligible individuals: CDEC mentioned the uncertainty in the amount of individuals with moderately severe to significant hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some people who will be labeled as obtaining gentle or average disorder can have a critical bleeding https://emperoru357vxy2.bloggactivo.com/profile